Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Erinacine A** is a naturally occurring diterpenoid isolated from the mycelium and fruiting bodies of the medicinal mushroom *Hericium erinaceus* (lion’s mane mushroom)[2][6]. It is best known for its **neuroprotective, neuroregenerative, antidepressant-like, anti-inflammatory, antioxidant, and anti-cancer properties**. Mechanistically, it promotes nerve growth factor (NGF) synthesis and has been shown to activate neurotrophic signaling (BDNF/TrkB/PI3K/Akt/GSK-3β), modulate monoamine neurotransmitter levels (dopamine, serotonin, norepinephrine), inhibit inflammatory mediators (NF-κB, IL-6, TNF-α, iNOS, MAPK), induce antioxidant pathways (Nrf2/HO-1/SOD1), and reduce amyloid-β accumulation associated with neurodegenerative processes[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on erinacine A.